Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction

Oliver Borst, Patrick Munzer, Nada Alnaggar, Sascha Geue, Roland Tegtmeyer, Dominik Rath, Michal Droppa, Peter Seizer, Stefan Heitmeier, Johan W. M. Heemskerk, Lisa K. Jennings, Robert F. Storey, Dominick J. Angiolillo, Bianca Rocca, Henri Spronk, Hugo Ten Cate, Meinrad Gawaz, Tobias Geisler

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)715-730
Number of pages16
JournalBlood advances
Volume2
Issue number6
DOIs
Publication statusPublished - 27 Mar 2018

Keywords

  • ACUTE CORONARY SYNDROME
  • ANTIPLATELET THERAPY
  • THROMBIN GENERATION
  • PLATELET REACTIVITY
  • ATRIAL-FIBRILLATION
  • ARTERY-DISEASE
  • ACTIVATION
  • TRIAL
  • HMGB1
  • RECRUITMENT

Cite this

Borst, O., Munzer, P., Alnaggar, N., Geue, S., Tegtmeyer, R., Rath, D., Droppa, M., Seizer, P., Heitmeier, S., Heemskerk, J. W. M., Jennings, L. K., Storey, R. F., Angiolillo, D. J., Rocca, B., Spronk, H., Ten Cate, H., Gawaz, M., & Geisler, T. (2018). Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. Blood advances, 2(6), 715-730. https://doi.org/10.1182/bloodadvances.2017013573